Sponsored diagnostic testing programs for Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord, leading to muscle weakness and loss of function. While most cases are sporadic, some are linked to inherited variants, making genetic evaluation useful for diagnosis, care planning, and identifying research opportunities.
2 programs found for Amyotrophic Lateral Sclerosis (ALS)
The ALS Identified Program enables clinicians in the US and Puerto Rico to access a broad genetic test for patients with diagnosed or familial ALS, at no cost. This program supports diagnostic clarity, helps inform prognosis and care planning, and can facilitate family counseling or trial eligibility. All costs are covered — there is no charge to the patient, provider, or payer.
In collaboration with Ionis Pharmaceuticals, this program offers genetic testing for amyotrophic lateral sclerosis (ALS), a neurodegenerative condition involving motor neuron degeneration in the cortex, brain stem, and spinal cord. Testing is available to eligible patients in the U.S. and Canada with a clinical diagnosis or family history of ALS. All tests must be ordered by a qualified healthcare provider.
